LMR Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

LMR Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-70,000	Closed	-$1.49M	–	1497
2025 Q3	$1.49M	Buy	+70,000	New	+$1.66M	0.01%	820

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

LMR Partners's ACAD Position: Q4 2020 in Review

LMR Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 27,055 shares — an estimated $1.12M sold.

LMR Partners first reported a position in ACAD in Q2 2016 and held it in 4 quarters. The position peaked at $1.59M in Q3 2016. 307 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

LMR Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
LMR Partners sold 27,055 Acadia Pharmaceuticals shares in Q4 2020, an estimated $1.12M.
LMR Partners first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 4 quarters.
LMR Partners's Acadia Pharmaceuticals position peaked at $1.59M in Q3 2016.
307 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on LMR Partners's 13F filing for Q4 2020, filed 16 Feb 2021.